Polymorphisms in the hMSH 2 Gene and the Risk of Primary Lung Cancer

Polymorphisms in the DNA repair genes may be associated with differences in the capacity to repair DNAdamage, and so this can influence an individual’s susceptibility to lung cancer. To test this hypothesis, we investigated the association of hMSH2 118T>C, IVS1+9G>C, IVS10+12A>G, and IVS12 6T>C genotypes and their haplotypes with the risk of lung cancer in a Korean population. The hMSH2 genotypes were determined in 432 lung cancer patients and in 432 healthy controls who were frequency matched for age and gender. The hMSH2 haplotypes were estimated based on a Bayesian algorithm using the Phase program. The presence of at least one IVS10+12G allele was associated with a significantly decreased risk of adenocarcinoma, as compared with the IVS10+12AA genotype [adjusted odds ratio (OR), 0.59; 95% confidence interval (95% CI), 0.40-0.88; P = 0.01], and the presence of at least one IVS12-6C allele was associated with a significantly increased risk of adenocarcinoma, as compared with the IVS12-6TT genotype (adjusted OR, 1.52; 95% CI, 1.02-2.27; P = 0.04). Consistent with the results of the genotyping analysis, the TGGT haplotype with no risk allele was associated with a significantly decreased risk of adenocarcinoma, as compared with the TCAC haplotype with two risk allele [i.e., IVS10+12A and IVS12-6C allele; adjusted OR, 0.49; 95% CI, 0.30-0.78; P = 0.003 and Pc (Bonferroni corrected P value) = 0.012]. The effect of the hMSH2 haplotypes on the risk of adenocarcinoma was statistically significant in the never smokers and younger individuals (adjusted OR, 0.45; 95% CI, 0.27-0.75; P = 0.002 and Pc = 0.004; and adjusted OR, 0.44; 95% CI, 0.23-0.85; P = 0.014 and Pc = 0.028, respectively) but not in the ever-smokers and older individuals. These results suggest that the hMSH2 polymorphisms and their haplotypes may be an important genetic determinant of adenocarcinoma of the lung, particularly in never smokers. (Cancer Epidemiol Biomarkers Prev 2006;15(4):762–8)

[1]  W. Hsu,et al.  Promoter Hypermethylation Is the Predominant Mechanism in hMLH1 and hMSH2 Deregulation and Is a Poor Prognostic Factor in Nonsmoking Lung Cancer , 2005, Clinical Cancer Research.

[2]  S. Leng,et al.  The Association of XRCC1 Haplotypes and Chromosomal Damage Levels in Peripheral Blood Lymphocyte among Coke-Oven Workers , 2005, Cancer Epidemiology Biomarkers & Prevention.

[3]  J. Park,et al.  Vascular Endothelial Growth Factor Gene Polymorphisms and Risk of Primary Lung Cancer , 2005, Cancer Epidemiology Biomarkers & Prevention.

[4]  A. Marchetti,et al.  EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Park,et al.  DNMT3B polymorphisms and risk of primary lung cancer. , 2004, Carcinogenesis.

[6]  Joachim Herz,et al.  Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? , 2004, Trends in molecular medicine.

[7]  Christine B Ambrosone,et al.  SNPs, haplotypes, and cancer: applications in molecular epidemiology. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[8]  K. Matsuo,et al.  Polymorphism in the hMSH2 gene (gIVS 12-6T-->C) and risk of non-Hodgkin lymphoma in a Japanese population. , 2003, Cancer genetics and cytogenetics.

[9]  V. Gonçalves,et al.  Novel MLH1 mutations and a novel MSH2 polymorphism identified by SSCP and DHPLC in Portuguese HNPCC families , 2003, Human mutation.

[10]  Alexandra G. Smith,et al.  An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Chih-Yi Chen,et al.  Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. , 2003, The Journal of clinical investigation.

[12]  C. Ulrich,et al.  Polymorphisms in DNA repair genes and associations with cancer risk. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[13]  H. Bernstein,et al.  DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. , 2002, Mutation research.

[14]  A. Duval,et al.  Mutations at coding repeat sequences in mismatch repair-deficient human cancers: toward a new concept of target genes for instability. , 2002, Cancer research.

[15]  M. Benito,et al.  Prevalence of germline mutations of MLH1 and MSH2 in hereditary nonpolyposis colorectal cancer families from Spain , 2002, International journal of cancer.

[16]  J. Park,et al.  Lys751Gln polymorphism in the DNA repair gene XPD and risk of primary lung cancer. , 2002, Lung cancer.

[17]  R. Scott,et al.  Mutation analysis of MLH1 and MSH2 genes performed by denaturing high-performance liquid chromatography. , 2002, Journal of biochemical and biophysical methods.

[18]  C. Paz-y-Miño,et al.  A polymorphism in the hMSH2 gene (gIVS12-6T>C) associated with non-Hodgkin lymphomas. , 2002, Cancer genetics and cytogenetics.

[19]  A. Bellacosa.  Functional interactions and signaling properties of mammalian DNA mismatch repair proteins , 2001, Cell Death and Differentiation.

[20]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[21]  Richard D. Wood,et al.  Human DNA Repair Genes , 2001, Science.

[22]  R Judson,et al.  Notes from the SNP vs. haplotype front. , 2001, Pharmacogenomics.

[23]  H. Jeon,et al.  Microsatellite alteration in histologically normal lung tissue of patients with non-small cell lung cancer. , 2000, Lung cancer.

[24]  P. Maloney,et al.  hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. , 2000, Cancer research.

[25]  N. Risch.  Searching for genetic determinants in the new millennium , 2000, Nature.

[26]  C. Harris,et al.  Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R Judson,et al.  The predictive power of haplotypes in clinical response. , 2000, Pharmacogenomics.

[28]  G. Capellá,et al.  Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer , 2000, British Journal of Cancer.

[29]  N. Geacintov,et al.  Mismatch Repair Processing of Carcinogen-DNA Adducts Triggers Apoptosis , 1999, Molecular and Cellular Biology.

[30]  M. J. Hickman,et al.  Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Spitz,et al.  Ethnic differences in poly(ADP-ribose) polymerase pseudogene genotype distribution and association with lung cancer risk. , 1999, Carcinogenesis.

[32]  J. Palazzo,et al.  MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. , 1999, Human molecular genetics.

[33]  R. Kolodner,et al.  Physical interaction between components of DNA mismatch repair and nucleotide excision repair. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[35]  K. Maruyama,et al.  Promoter analysis of the human mismatch repair gene hMSH2. , 1998, Gene.

[36]  M. Spitz,et al.  Reduced DNA repair capacity in head and neck cancer patients. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[37]  I. M. Jones,et al.  Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation? , 1998, Mutation research.

[38]  Carr J. Smith,et al.  An international literature survey of "IARC Group I carcinogens" reported in mainstream cigarette smoke. , 1997, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[39]  H. Schackert,et al.  An intronic germline transition in the HNPCC gene hMSH2 is associated with sporadic colorectal cancer. , 1997, European journal of cancer.

[40]  A. Horii,et al.  Alternative splicing of hMSH2 in normal human tissues , 1997, Human Genetics.

[41]  A. Lindblom,et al.  Low frequency of hMSH2 mutations in Swedish HNPCC families , 1997, International journal of cancer.

[42]  A. Viel,et al.  Characterization of MSH2 and MLH1 mutations in Italian families with hereditary nonpolyposis colorectal cancer , 1997, Genes, chromosomes & cancer.

[43]  J. Ivanovich,et al.  Mutations in MLH1 are more frequent than in MSH2 in sporadic colorectal cancers with microsatellite instability , 1997, Genes, chromosomes & cancer.

[44]  A. Carothers,et al.  Microsatellite instability and the role of hMSH2 in sporadic colorectalcancer. , 1996, Oncogene.

[45]  C. Eithz,et al.  [Hereditary nonpolyposis colorectal cancer]. , 1996, Ugeskrift for laeger.

[46]  Z. Cohen,et al.  A truncated hMSH2 transcript occurs as a common variant in the population: implications for genetic diagnosis. , 1996, Cancer research.

[47]  C. Boland,et al.  Transcription-Coupled Repair Deficiency and Mutations in Human Mismatch Repair Genes , 1996, Science.

[48]  R. Lothe,et al.  Somatic mutations in the hMSH2 gene in microsatellite unstable colorectal carcinomas. , 1995, Human Molecular Genetics.

[49]  R. Kolodner.  Mismatch repair: mechanisms and relationship to cancer susceptibility. , 1995, Trends in biochemical sciences.

[50]  M. Bronner,et al.  A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. , 1995, Gastroenterology.

[51]  R. Lewontin,et al.  On measures of gametic disequilibrium. , 1988, Genetics.

[52]  G. Grimmer,et al.  Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. , 1983, Journal of the National Cancer Institute.

[53]  C. H. Kim,et al.  Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[54]  A. Viel,et al.  Characterization of MLH1 and MSH2 alternative splicing and its relevance to molecular testing of colorectal cancer susceptibility , 1998, Human Genetics.